Duke University
Durham, North Carolina, United States
Dr. Ortel is the Chief of Hematology at Duke University. He has a primary clinical interest and research expertise in hemostatic and thrombotic disorders. His research interests focus on rare thrombotic disorders, including antiphospholipid antibody syndrome (APS) and heparin-induced thrombocytopenia (HIT), as well as the development and management of novel antithrombotic therapies. As a member and Chair of the Lupus Anticoagulant/Phospholipid-dependent Antibodies Scientific Subcommittee of the International Society on Thrombosis and Haemostasis, he has co-authored guidelines on laboratory testing for lupus anticoagulants, anticardiolipin antibodies, and anti-b2-glycoprotein I antibodies. He is also an active clinical investigator, and was the PI for the BRIDGE trial, an NHLBI-supported, multi-center, prospective, randomized, double-blind study that investigated whether bridging therapy with a low-molecular weight heparin was necessary in patients with atrial fibrillation on chronic oral anticoagulant therapy with warfarin who needed anticoagulation temporarily withheld for a procedure. He is currently Study Chair for the ACTIV 4c Post-Hospital Thrombosis Prevention Study, investigating the use of extended thromboprophylaxis to prevent VTE following hospitalization with COVID-19. He has also collaborated with investigators at the Centers for Disease Control and Prevention to identify cases of the thrombosis and thrombocytopenia syndrome (TTS) in persons following vaccination against COVID-19 as well as to develop surveillance strategies to identify cases of venous thromboembolism using automated strategies to monitor the electronic medical record.
Disclosure information not submitted.
Tuesday, October 18, 2022
3:00 PM – 4:55 PM
Tuesday, October 18, 2022
3:25 PM – 3:45 PM
Tuesday, October 18, 2022
4:35 PM – 4:55 PM